Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press108210.17650/1726-9776-2007-3-1-30-32DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиIs hypercoagulation a predictor influencing the efficiency of immunotherapy for metastatic renal cancer?Гиперкоагуляция — прогностический фактор, влияющий на эффективность иммунотерапии у больных метастатическим раком почки?TimofeyevI. V.ТимофеевИ. В.
Russian Federation
MadzhugaA. V.МаджугаА. В.
Russian Federation
DemidovL. V.ДемидовЛ. В.
Russian Federation
SomonovaO. V.СомоноваО. В.
Russian Federation
KharkevichG. Yu.ХаркевичГ. Ю.
Russian Federation
YelizarovaA. L.ЕлизароваА. Л.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical AcademyГУ РОНЦ им. Н.Н. Блохина РАМН, ММА им. И.М. Сеченова300320073130321502202015022020https://oncourology.abvpress.ru/oncur/article/view/1082

In experimental systems, interference with coagulation can affect tumor biology. Tumor-mediated activation of the hemostatic system has been implicated in both the formation of tumor stroma and the promotion of hematogenous metastasis. We emphasize that hypercoagulation is a frequent symptom in metastatic renal cell carcinoma (MRCC) patients and clinically correlates with progression of the disease. It has been suggested that hypercoagulation is a possible negative predictor for a response to immunotherapy in MRCC patients.

.

1. Kakkar A.K., Williamson R.C. Antithrombotic therapy in cancer. BMJ 1999; 318(7198): 1571—2.Kakkar A.K., Williamson R.C. Antithrombotic therapy in cancer. BMJ 1999; 318(7198): 1571—2.2. Kakkar A.K., DeRuvo N., Chinswangwatanakul V. et al. Extrinsicpathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004—5.Kakkar A.K., DeRuvo N., Chinswangwatanakul V. et al. Extrinsicpathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004—5.3. Kharkevich G., Tsimafeyeu I., Demidov L. Low-dose IL-2 in combination with IFN and 5-FU for metastatic renal cell carcinoma. J Eur Urol 2006;5(2 Suppl):286.Kharkevich G., Tsimafeyeu I., Demidov L. Low-dose IL-2 in combination with IFN and 5-FU for metastatic renal cell carcinoma. J Eur Urol 2006;5(2 Suppl):286.4. Misbah S.A., Shaheen P.E., Elson P.J. et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. JCO 2005;23:4599.Misbah S.A., Shaheen P.E., Elson P.J. et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. JCO 2005;23:4599.5. Sampson M.T., Kakkar A.K. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30(2): 201—7.Sampson M.T., Kakkar A.K. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30(2): 201—7.